Collectively, our work demonstrates a viable strategy of A2ARi in combination with inhibition of lipid peroxidation to improve persistence and functionality of ACT against cancer, contributing to the debate over the best way to target GPX4 for cancer therapy. Here, GPX4 is linked to cancer.